Sign In
Buy ZBIO
$17.40
+0.270 (+1.58%)
At Close: Jun 03, 2026
- The INDIGO study met its primary and all key secondary endpoints with statistically significant results - - Obexelimab significantly lowered the total amount of glucocorticoid use and reduced glucoc
Zenas BioPharma Announces Submission of Biologics License Application (BLA) to U.S. FDA for Obexelimab in IgG4-RD
07:05am, Thursday, 28'th May 2026
- BLA submission based on positive results from Phase 3 INDIGO trial - WALTHAM, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas,” “Zenas BioPharma” or the “Company”)
- Safety and efficacy results from the Phase 3 INDIGO trial to be presented by Emanuel Della Torre, M.D., Ph.D., on Thursday June 4, 2026, at 2:45 PM GMT -
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:15pm, Monday, 18'th May 2026
WALTHAM, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader
- Phase 1 trial designed to evaluate the safety, tolerability, and pharmacokinetic properties of ZB021 in healthy volunteers and to establish proof-of-concept in patients with plaque psoriasis -
Zenas BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Update
06:00am, Wednesday, 13'th May 2026
– Obexelimab marketing applications for the treatment of IgG4-RD on-target for submission to the FDA this quarter and the EMA in H2 2026 based on the Phase 3 INDIGO IgG4-RD trial results –
Zenas: 'Strong Buy' On Obexelimab Enhancement And Expected SLE Data Q4 2026
02:36pm, Thursday, 30'th Apr 2026
Zenas BioPharma, Inc. maintains a Strong Buy rating, driven by obexelimab's positive phase 3 results in IgG4-RD and regulatory filings planned for 2026. ZBIO is advancing obexelimab into the large SLE
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:15pm, Friday, 17'th Apr 2026
WALTHAM, Mass., April 17, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leade
Zenas BioPharma (NASDAQ:ZBIO) Shares Up 7.6% on Insider Buying Activity
01:19am, Friday, 03'rd Apr 2026
Zenas BioPharma, Inc. (NASDAQ: ZBIO - Get Free Report) shares rose 7.6% during trading on Thursday after an insider bought additional shares in the company. The stock traded as high as $22.12 and last
Zenas BioPharma (NASDAQ:ZBIO) versus Twist Bioscience (NASDAQ:TWST) Critical Analysis
01:28am, Saturday, 28'th Mar 2026
Twist Bioscience (NASDAQ: TWST - Get Free Report) and Zenas BioPharma (NASDAQ: ZBIO - Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two businesses
WALTHAM, Mass., March 27, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas,” “Zenas BioPharma” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company com
Zenas BioPharma Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032 and Common Stock
04:01pm, Thursday, 26'th Mar 2026
WALTHAM, Mass., March 26, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas,” “Zenas BioPharma” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company com
Zenas BioPharma, Inc. (NASDAQ:ZBIO) Receives Average Recommendation of “Hold” from Analysts
04:19am, Thursday, 26'th Mar 2026
Zenas BioPharma, Inc. (NASDAQ: ZBIO - Get Free Report) has received a consensus recommendation of "Hold" from the nine research firms that are currently covering the company, MarketBeat.com reports. T
ENAVATE's Zenas Bio Pharma add Is a Footnote — The Obexelimab Pipeline Is What to Watch
02:03pm, Saturday, 21'st Mar 2026
ENAVATE Added 157,800 shares of Zenas BioPharma worth an estimated $5.19 million (based on quarterly average price). The quarter-end position value increased by $58.80 million, reflecting both trading
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06:01pm, Monday, 16'th Mar 2026
WALTHAM, Mass., March 16, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leade
